Author

Yasaman Mortazavi

Gladstone Institutes

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:genetic perturbation / CRISPR· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Alexander MarsoniD· 2 shared Alexis TalbotiD· 2 shared Chang LiuiD· 2 shared Jing-Yi ChungiD· 2 shared Joseph J. MuldooniD· 2 shared Justin EyquemiD· 2 shared Vincent AllainiD· 2 shared William A. NybergiD· 2 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Alexander MarsonORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple Myeloma

Alexis Talbot, K Li, Jae Hyun J. Lee, Shanshan Lang, Chang Liu, Nechama Kalter, Zhongmei Li, Yasaman Mortazavi, Niran Almudhfar, Joseph J. Muldoon, Vincent Allain, William A. Nyberg, Jing-Yi Chung, Charlotte Wang, Zhongxia Qi, , Brian Rudolph Shy

This paper develops a non-viral BCMA CAR-T therapy using CRISPR and 1XX signaling, showing improved safety, potency, and persistence in multiple myeloma.

bioRxiv · May 5, 2026 · PreprintCancer Biology

Site-specific genome engineering of primary human natural killer cells for programmable anti-tumor function

Vincent Allain, Allison Grace Rothrock, Pierre-Louis Bernard, William A. Nyberg, Alexis Talbot, Joseph J. Muldoon, Jing-Yi Chung, Angela To, Christopher R. Chang, Gabriella R. Kimmerly, Chang Liu, Tasha Tsao, Yasaman Mortazavi, Jin Seo, Zhongmei Li, , Justin Eyquem

This paper develops a genome engineering workflow for primary human NK cells using CRISPR/Cas9 and AAV6 to integrate and disrupt genes, enhancing anti-tumor function through targeted CAR expression.

bioRxiv · Oct 5, 2025 · PreprintImmunology